zolbetuximab Vyloy
Selected indexed studies
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. (Nat Med, 2023) [PMID:37524953]
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. (Lancet, 2023) [PMID:37068504]
- Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. (N Engl J Med, 2024) [PMID:39282934]
_Worker-drafted node — pending editorial review._
Connections
zolbetuximab Vyloy is a side effect of
Sources
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. (2023) pubmed
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. (2023) pubmed
- Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. (2024) pubmed
- Practical Management of Zolbetuximab Administration: The Project VYLOY Initiative. (2025) pubmed
- Zolbetuximab: First Approval. (2024) pubmed
- Characterization of zolbetuximab in pancreatic cancer models. (2019) pubmed
- Claudin 18.2 as a novel therapeutic target. (2024) pubmed
- ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. (2023) pubmed
- FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. (2021) pubmed
- Zolbetuximab (Vyloy) for gastric and gastroesophageal carcinoma. (2024) pubmed